Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 11;1(2):CASE2058. doi: 10.3171/CASE2058

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The authors

CC BY-NC-ND 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

FIG. 2. — Case 3. Preoperative axial contrast-enhanced T1-weighted MRI (A) demonstrates patient’s initial lesion within the right sphenoid sinus (white dotted arrow), pathology-proven ENB. Postoperative axial contrast-enhanced fat-saturated T1-weighted MRI (B) demonstrates dural-based plaque-like enhancement along the right cavernous sinus (white arrow) and normal enhancement of the pituitary gland (black arrow). Axial CT (C and D) and fused axial [68Ga]-DOTATATE PET/CT windowed at SUV 0-15 (E and F) demonstrate expected postsurgical appearance of the sinuses without evidence of DOTATATE avidity to suggest residual or recurrent disease (C and E) as well as a focus of intense DOTATATE avidity, SUV 11.0, along the right cavernous sinus (white arrow, F), corresponding to the dura-based plaque-like enhancement (B), compatible with a meningioma. Physiological DOTATATE avidity is noted in the pituitary gland (black arrow, F). [68Ga]-DOTATATE PET MIP (G) demonstrates normal physiological uptake in the pituitary gland (black arrow) and a focus of DOTATATE avidity corresponding to the right cavernous sinus meningioma (white arrow) without evidence of recurrent or metastatic disease.